1 report

  • ASTRAZENECA ENTERS INTO LICENSING AGREEMENT WITH SYNAIRGEN FOR SNG001
  • PARTNERSHIPS

Inhaled IFN-beta has been effective at accelerating a recovery of virus-induced losses in lung function in two Phase II asthma trials (one conducted by Synairgen and one conducted by AstraZeneca).

  • Asthma
  • Healthcare
  • Pharmaceutical
  • United Kingdom
  • Synairgen plc